In a perspective paper published in The American Journal of Clinical Nutrition, a team of researchers and health experts calls for a ‘paradigm shift’ in how public health agencies address hypertension.

The post Scientists Propose New Strategy in Fight against High Blood Pressure appeared first on Sci.News: Breaking Science News.

In a new review paper, Dr. Gregory Marcus from the University of California, San Francisco and colleagues analyzed decades of research on how caffeine -- most often consumed as coffee -- affects the heart and its risk factors.

The post Moderate Coffee and Caffeine Intake Poses Little Heart Risk, and May Even Help appeared first on Sci.News: Breaking Science News.

A new analysis of data from the Western Australian-based Raine Study suggests that two humble vegetable groups -- legumes and cruciferous vegetables -- may play an outsize role in protecting young adults from early cardiometabolic risk, though the benefits appear to diverge sharply between men and women.

The post Beans and Broccoli Linked to Lower Heart Risk in Young Adults appeared first on Sci.News: Breaking Science News.

In a groundbreaking longitudinal study encompassing nearly half a million individuals, researchers have unveiled intricate patterns and biological underpinnings that link cardiometabolic diseases (CMDs) and depression. These two prevalent and often coexisting health conditions have long posed challenges due to their complex interaction and compounded risk on mortality. Now, through a multinational, multi-omic analytic approach, this study sheds new light on how these diseases develop, interlace over time, and ultimately impact life expectancy, offering hope for earlier detection and more precise interventions.

Cardiometabolic diseases—which include chronic conditions such as cardiovascular disease, type 2 diabetes, and metabolic syndrome—are among the leading causes of death globally. Depression, meanwhile, remains a colossal mental health burden, often running parallel to various physical ailments. The coexistence, or multimorbidity, of CMDs and depression exacerbates health outcomes significantly, yet the trajectory of how one condition progresses to include the other and the biological mechanisms driving this interaction have remained elusive.

Leveraging data from the UK Biobank, the largest population-based health cohort, the study followed 467,592 participants initially free of both CMD diagnoses and depression. Over a 14.6-year period, the scientists meticulously chronicled disease transitions using advanced multistate models. These allowed them not only to identify disease onset patterns but also to map complex pathways outlining progression from health to single disease states and then to multimorbidity.

The findings revealed that within the follow-up window, more than 64,000 participants developed CMD alone, while approximately 17,500 were diagnosed with depression exclusively. Crucially, over 6,100 individuals progressed to multimorbidity, reflecting the convergence of these conditions in a significant subset of the population. Importantly, the risk of subsequently developing the alternate condition was substantially elevated for those already affected by either CMD or depression, underscoring the bidirectional relationship between physical and mental health.

Further delving into survival outcomes, the researchers observed that individuals with multimorbidity faced a 13 to 22 percent increase in mortality risk compared to those free of disease, accompanied by a marked reduction in life expectancy averaging between 3.6 to 3.8 years. Such stark contrasts reinforce the clinical urgency of understanding and managing the intersection of CMDs and depression rather than treating them in isolation.

However, a nuanced discovery emerged from the survival analysis: the mortality impact of coexisting CMD and depression appeared additive rather than synergistic. This suggests that while coexistence heightens risk, the two diseases may operate through largely independent pathways driving mortality, a revelation that could recalibrate how treatment priorities are structured.

To decipher biological signatures predictive of disease progression and multimorbidity, the study incorporated multi-omics platforms—comprehensive analyses including proteomics, metabolomics, genomics, and methylomics. These high-dimensional tools allow scientists to detect subtle molecular changes reflecting pathophysiological shifts and prognostic biomarkers far earlier than clinical symptoms emerge.

Remarkably, proteomic models stood out in their predictive prowess. When applied to the 15-year risk horizon for CMD-depression transitions, these models achieved area-under-the-curve (AUC) values ranging between 0.70 and 0.91. This performance significantly eclipsed that of traditional clinical risk models, heralding a new dawn where molecular profiling could transform risk stratification and preventive strategies.

Distinct multi-omic signatures were identified at each disease transition point—whether from health to CMD alone, health to depression alone, or the combined pathway leading to multimorbidity. These signatures could reflect unique biological processes such as inflammatory cascades, metabolic dysregulation, neuroendocrine changes, or immune system perturbations, each contributing distinctively to disease progression.

The implications of these findings are far-reaching. With multimorbidity presenting as a growing global health challenge, understanding its trajectory and molecular footprints empowers clinicians and researchers to design targeted interventions that transcend symptom management. Early identification of individuals at highest risk via omic biomarkers could enable precision medicine approaches that pre-empt illness onset or halt progression.

Furthermore, by elucidating the distinct yet interconnected biological pathways linking CMDs and depression, this research challenges the traditionally siloed view of mental and physical health. It advocates for integrated care models that address the whole person rather than fragmented disease entities, a paradigm shift essential for improving patient outcomes in real-world settings.

The study also leverages rigorous multistate modeling, a sophisticated statistical technique allowing for dynamic representation of illness progression over time. This approach captures the complexity inherent in chronic disease trajectories, encompassing not only onset but transitions between disease states and eventual mortality. Such modeling enhances the granularity of epidemiological insights far beyond conventional methods.

As large-scale biobanks increasingly incorporate multi-omic data, the ability to unravel disease biology at unprecedented depth will only grow. The present study exemplifies how marrying big data with cutting-edge analytic frameworks can unveil novel insights into multimorbidity, transforming epidemiology into a powerful tool for precision health.

This research arrives at a critical juncture where global populations face rising burdens of chronic diseases intertwined with mental health challenges. Targeted, biologically informed strategies could ease the strain on healthcare systems and improve quality of life for millions living with overlapping disease burdens.

While promising, the findings also urge cautious optimism. The translation of molecular signatures into routine clinical tools requires further validation and contextualization across diverse ancestral and environmental backgrounds. However, these initial steps firmly establish a conceptual blueprint for future studies to build upon.

Taken together, this extensive investigation pioneers a new frontier in understanding the intertwined evolution of cardiometabolic diseases and depression. By uniting longitudinal clinical data with multi-omics analyses and sophisticated modeling, it heralds a transformative approach toward unraveling multimorbidity’s mysteries and paves the way for early, targeted prevention.

The convergence of CMDs and depression, previously viewed as a devastating clinical overlap, now emerges as a tractable problem awaiting targeted intervention—fueling hope that integrated molecular insights will soon translate into lifesaving real-world applications. This revolutionary research sets the stage for a future where vulnerability to complex chronic disease is revealed well before symptoms arise, opening unprecedented avenues for personalized health preservation.

Subject of Research:
Multi-omic signatures and disease trajectories linking cardiometabolic diseases and depression

Article Title:
Multi-omic signatures and trajectories of cardiometabolic diseases and depression

Article References:

Yang, G., Jiang, X., Wang, J. et al. Multi-omic signatures and trajectories of cardiometabolic diseases and depression.
Nat. Mental Health (2026). https://doi.org/10.1038/s44220-026-00678-6

Image Credits: AI Generated

DOI:
https://doi.org/10.1038/s44220-026-00678-6

Atherosclerosis remains the foremost cause of cardiovascular disease-related morbidity and mortality globally, posing a substantial challenge to healthcare systems. Although traditional risk factors such as diet, lifestyle, and genetics have been extensively studied, recent advances have illuminated the pivotal role played by epigenetic mechanisms in shaping the onset and progression of atherosclerotic disease. Epigenetics, the reversible modulation of gene expression without alterations to the DNA sequence, encompasses DNA methylation, histone modifications, and non-coding RNAs, all of which intricately orchestrate cellular behavior within vascular tissues.

Emerging research reveals that DNA methylation patterns, both globally across the genome and in gene-specific loci, critically regulate cellular proliferation and inflammatory responses integral to atherogenesis. Hypomethylation or hypermethylation at particular sites can drastically affect the transcriptional activity of genes responsible for maintaining vascular homeostasis. This phenomenon underscores a dynamic regulatory system where environmental cues and pathological stimuli can induce lasting epigenomic changes that propagate vascular dysfunction and inflammation.

Histone post-translational modifications add another sophisticated layer to this epigenetic landscape. Primarily involving acetylation and methylation of histone proteins, these modifications influence chromatin structure and, consequently, gene accessibility. Within atherosclerotic plaques, histone modifications have been shown to govern networks of genes related to lipid metabolism, cellular plasticity, and inflammatory signaling. Such modifications enable vascular cells to adapt to inflammatory and metabolic stress by modulating transcriptional programs essential for plaque development and instability.

Non-coding RNAs have further expanded the complexity of epigenetic regulation within the vascular milieu. Long non-coding RNAs (lncRNAs) shape the transcriptomic profiles of specific cell types and exert control over the localization and activity of epigenetic enzymes. This targeting ensures that epigenetic remodeling is not only precise but also tailored to cellular needs in the context of vascular remodeling. Concurrently, microRNAs (miRNAs), small regulatory RNAs, predominantly mediate post-transcriptional gene silencing but have been identified to participate in non-canonical functions that influence vascular cell phenotype and immune responses.

The integration of multi-omics approaches, combining epigenomics, transcriptomics, and proteomics, has revolutionized our understanding of the cell-specific epigenetic contributions in atherosclerosis. These technological advancements enable the dissection of complex intercellular interactions within plaques and facilitate the mapping of genetically associated loci to discrete epigenetic modifications. This multidimensional insight is vital to unraveling the heterogeneity of atherosclerotic lesions and their diverse clinical manifestations.

In vascular endothelial cells, epigenetic alterations modulate barrier function, inflammation, and response to shear stress, all of which are critical in the initial stages of atherogenesis. Endothelial dysfunction triggered by epigenetic dysregulation sets the stage for immune cell recruitment and plaque formation. Meanwhile, vascular smooth muscle cells (VSMCs) exhibit remarkable plasticity through epigenetic reprogramming that drives their phenotypic switch from a contractile to a synthetic state, facilitating extracellular matrix remodeling and plaque stability or vulnerability.

Immune cells within the atherosclerotic microenvironment are also subject to profound epigenetic modulation. Macrophages, T cells, and other leukocytes display distinct epigenetic signatures that influence their activation states and inflammatory profiles. Epigenetic memory within these immune populations can perpetuate chronic vascular inflammation, underscoring the need for targeted interventions that modulate immune cell epigenomes to mitigate atherosclerotic progression.

Preclinical studies have leveraged these mechanistic insights to explore epigenetic drug candidates capable of attenuating plaque burden and vascular inflammation. Histone deacetylase inhibitors, DNA methylation modulators, and RNA-based therapeutics have demonstrated efficacy in experimental models, highlighting their potential to recalibrate aberrant gene expression patterns driving disease. However, challenges remain in achieving cell-type specificity, minimizing off-target effects, and ensuring the durability and safety of such interventions in humans.

A critical hurdle for translational success lies in the delivery mechanisms for epigenetic therapies. Nanoparticle-based systems and ligand-targeted delivery platforms are under investigation to enhance precision targeting of vascular and immune cells within plaques. These delivery technologies aim to maximize therapeutic benefit while circumventing systemic toxicity, thereby advancing the clinical applicability of epigenetic modulators.

Long-term safety is another paramount consideration as epigenetic drugs inherently affect gene regulation, potentially leading to unforeseen consequences. Rigorous preclinical evaluation and carefully designed clinical trials are imperative to balance efficacy with safety, ensuring that epigenetic therapies can be integrated into cardiovascular medicine without triggering deleterious off-target effects.

The prospect of leveraging epigenetic regulation heralds a transformative shift in cardiovascular therapeutics, enabling precision medicine tailored to an individual’s unique epigenomic landscape. By elucidating the dynamic and reversible nature of epigenetic modifications in vascular cells and immune populations, researchers are charting new pathways to mitigate atherosclerosis beyond conventional lipid-lowering and anti-inflammatory strategies.

Continued exploration into the interplay between genetic predisposition and environmental influences mediated by epigenetic mechanisms promises to deepen our understanding of atherosclerosis pathobiology. This holistic view integrates molecular, cellular, and systemic insights, empowering the development of sophisticated therapeutics capable of interrupting the disease process at its regulatory roots.

In summary, the frontier of atherosclerosis research lies at the intersection of epigenetics and vascular biology. The potential to manipulate gene expression programs with high specificity and reversibility offers an unprecedented opportunity to combat the global burden of cardiovascular disease. As the field advances, collaboration across disciplines and innovative technological approaches will be essential to realize the therapeutic promise of epigenetic modulation in clinical practice.

With ongoing efforts focused on unraveling cell-specific epigenetic mechanisms, refining drug delivery technologies, and ensuring long-term treatment safety, the era of epigenetics-driven precision cardiology is on the horizon. This paradigm shift not only holds the key to diminishing the impact of atherosclerosis but also exemplifies the broader potential of epigenetic therapies across complex diseases.

Subject of Research: Epigenetic regulation mechanisms in atherosclerosis and their potential for therapeutic intervention.

Article Title: Epigenetic regulation in atherosclerosis and its therapeutic potential

Article References:
Santovito, D., Atzler, D. & Weber, C. Epigenetic regulation in atherosclerosis and its therapeutic potential. Nat Rev Cardiol (2026). https://doi.org/10.1038/s41569-026-01313-8

Image Credits: AI Generated